James Swanson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10777300/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Randomized Controlled Trial of Interventions for Growth Suppression in Children With Attention-Deficit/Hyperactivity Disorder Treated With Central Nervous System Stimulants. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, 1330-1341.	0.3	22
2	Mutations in sphingolipid metabolism genes are associated with ADHD. Translational Psychiatry, 2020, 10, 231.	2.4	7
3	ADGRL3 (LPHN3) variants predict substance use disorder. Translational Psychiatry, 2019, 9, 42.	2.4	29
4	Meeting Report: Growth and Social Environment. Proceedings of the 25th Aschauer Soiree, held at Krobielowice, Poland, November 18th 2017. Pediatric Endocrinology Reviews, 2018, 15, 319-329.	1.2	0
5	<i> <scp>ADGRL</scp> 3 (<scp>LPHN</scp> 3) </i> variants are associated with a refined phenotype of <scp>ADHD</scp> in the <scp>MTA</scp> study. Molecular Genetics & Genomic Medicine, 2016, 4, 540-547.	0.6	35
6	Life Span Studies of ADHD—Conceptual Challenges and Predictors of Persistence and Outcome. Current Psychiatry Reports, 2016, 18, 111.	2.1	93
7	Exploring the associations between microRNA expression profiles and environmental pollutants in human placenta from the National Children's Study (NCS). Epigenetics, 2015, 10, 793-802.	1.3	91
8	Developmental processes in peer problems of children with attention-deficit/hyperactivity disorder in The Multimodal Treatment Study of Children With ADHD: Developmental cascades and vicious cycles—CORRIGENDUM. Development and Psychopathology, 2014, 26, 287-287.	1.4	2
9	Prevalence and Characteristics of School Services for High School Students with Attention-Deficit/Hyperactivity Disorder. School Mental Health, 2014, 6, 264-278.	1.1	33
10	Human placental study of genetics/genomic, environmental contaminant and morphology assessments from 12 U.S. Counties – Methods and results from the U.S. National Children's Study (NCS). Placenta, 2014, 35, A2.	0.7	1
11	Does childhood positive self-perceptual bias mediate adolescent risky behavior in youth from the MTA study?. Journal of Consulting and Clinical Psychology, 2013, 81, 846-858.	1.6	21
12	Understanding the Effects of Stimulant Medications on Cognition in Individuals with Attention-Deficit Hyperactivity Disorder: A Decade of Progress. Neuropsychopharmacology, 2011, 36, 207-226.	2.8	219
13	DRD4 and DAT1 in ADHD: Functional neurobiology to pharmacogenetics. Pharmacogenomics and Personalized Medicine, 2010, 3, 61.	0.4	16
14	Developmental processes in peer problems of children with attention-deficit/hyperactivity disorder in The Multimodal Treatment Study of Children With ADHD: Developmental cascades and vicious cycles. Development and Psychopathology, 2010, 22, 785-802.	1.4	108
15	Adverse Reactions to Methylphenidate Treatment for Attention-Deficit/Hyperactivity Disorder: Structure and Associations with Clinical Characteristics and Symptom Control. Journal of Child and Adolescent Psychopharmacology, 2009, 19, 683-690.	0.7	57
16	Developmental Origins of Health and Disease: Brief History of the Approach and Current Focus on Epigenetic Mechanisms. Seminars in Reproductive Medicine, 2009, 27, 358-368.	0.5	775
17	Developmental Origins of Health and Disease: Environmental Exposures. Seminars in Reproductive Medicine, 2009, 27, 391-402.	0.5	181
18	Evidence, Interpretation, and Qualification From Multiple Reports of Long-Term Outcomes in the Multimodal Treatment Study of Children With ADHD (MTA). Journal of Attention Disorders, 2008, 12, 4-14.	1.5	113

#	Article	IF	CITATIONS
19	Evidence, Interpretation, and Qualification From Multiple Reports of Long-Term Outcomes in the Multimodal Treatment Study of Children With ADHD (MTA). Journal of Attention Disorders, 2008, 12, 15-43.	1.5	83
20	Pharmacokinetics of Methylphenidate in Preschoolers with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2007, 17, 153-164.	0.7	58
21	A Twin Study of Attention-Deficit/Hyperactivity Disorder Dimensions Rated by the Strengths and Weaknesses of ADHD-Symptoms and Normal-Behavior (SWAN) Scale. Biological Psychiatry, 2007, 61, 700-705.	0.7	101
22	Efficacy and Safety of Immediate-Release Methylphenidate Treatment for Preschoolers With ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1284-1293.	0.3	409
23	The National Children's Study: A 21-Year Prospective Study of 100 000 American Children. Pediatrics, 2006, 118, 2173-2186.	1.0	158
24	Safety and Tolerability of Methylphenidate in Preschool Children With ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1294-1303.	0.3	211
25	Pharmacogenetics of Methylphenidate Response in Preschoolers With ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1314-1322.	0.3	116
26	Stimulant-Related Reductions of Growth Rates in the PATS. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1304-1313.	0.3	201
27	Rationale, Design, and Methods of the Preschool ADHD Treatment Study (PATS). Journal of the American Academy of Child and Adolescent Psychiatry, 2006, 45, 1275-1283.	0.3	125
28	Treatment-related changes in objectively measured parenting behaviors in the multimodal treatment study of children with attention-deficit/hyperactivity disorder Journal of Consulting and Clinical Psychology, 2006, 74, 649-657.	1.6	91
29	Dopamine receptor D4 (DRD4) gene in Han Chinese children with attention-deficit/hyperactivity disorder (ADHD): Increased prevalence of the 2-repeat allele. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 133B, 54-56.	1.1	74
30	Cost-Effectiveness of ADHD Treatments: Findings From the Multimodal Treatment Study of Children With ADHD. American Journal of Psychiatry, 2005, 162, 1628-1636.	4.0	138
31	The Services for Children and Adolescents–Parent Interview: Development and Performance Characteristics. Journal of the American Academy of Child and Adolescent Psychiatry, 2004, 43, 1334-1344.	0.3	104
32	Comparative Pharmacodynamics and Plasma Concentrations of d-threo-Methylphenidate Hydrochloride After Single Doses of d-threo-Methylphenidate Hydrochloride and d,l-threo-Methylphenidate Hydrochloride in a Double-Blind, Placebo-Controlled, Crossover Laboratory School Study in Children With Attention-Deficit/Hyperactivity Disorder. Journal of the	0.3	75
33	American Academy of Child and Adolescent Psychiatry, 2004, 43, 1422-1429. The effect of methylphenidate on three forms of response inhibition in boys with AD/HD. Journal of Abnormal Child Psychology, 2003, 31, 105-120.	3.5	148
34	ADHD Treatment With Once-Daily OROS Methylphenidate: Interim 12-Month Results From a Long-Term Open-Label Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2003, 42, 424-433.	0.3	132
35	Compliance with Stimulants for Attention-Deficit/ Hyperactivity Disorder. CNS Drugs, 2003, 17, 117-131.	2.7	135
36	Development of a New Once-a-Day Formulation of Methylphenidate for the Treatment of Attention-deficit/Hyperactivity Disorder. Archives of General Psychiatry, 2003, 60, 204.	13.8	228

JAMES SWANSON

#	Article	IF	CITATIONS
37	Future Directions in the Holistic Treatment of Children with Learning and Attention Disorders. , 2003, , 443-476.		0
38	Adaptationism and molecular biology: An example based on ADHD. Behavioral and Brain Sciences, 2002, 25, .	0.4	6
39	Genes and attention deficit hyperactivity disorder. Current Psychiatry Reports, 2001, 3, 92-100.	2.1	37
40	Genes and attention-deficit hyperactivity disorder. Clinical Neuroscience Research, 2001, 1, 207-216.	0.8	71
41	Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children*. Clinical Pharmacology and Therapeutics, 1999, 66, 295-305.	2.3	193
42	ASSESSMENT AND INTERVENTION FOR ATTENTION-DEFICIT/HYPERACTIVITY DISORDER IN THE SCHOOLS. Pediatric Clinics of North America, 1999, 46, 993-1009.	0.9	90
43	Cognitive neuroscience of attention deficit hyperactivity disorder and hyperkinetic disorder. Current Opinion in Neurobiology, 1998, 8, 263-271.	2.0	271
44	Effects of methylphenidate (Ritalin) on selective attention in hyperactive children. Journal of Abnormal Child Psychology, 1979, 7, 471-481.	3.5	27
45	STIMULANT EFFECTS ON COOPERATION AND SOCIAL INTERACTION BETWEEN HYPERACTIVEE CHILDREN AND THEIR MOTHERS. Journal of Child Psychology and Psychiatry and Allied Disciplines, 1978, 19, 13-22.	3.1	101
46	Time-Response Analysis of the Effect of Stimulant Medication on the Learning Ability of Children Referred for Hyperactivity. Pediatrics, 1978, 61, 21-29.	1.0	180